[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UA124353C2 - Нова сполука і її фармакологічно прийнятна сіль - Google Patents

Нова сполука і її фармакологічно прийнятна сіль

Info

Publication number
UA124353C2
UA124353C2 UAA201908271A UAA201908271A UA124353C2 UA 124353 C2 UA124353 C2 UA 124353C2 UA A201908271 A UAA201908271 A UA A201908271A UA A201908271 A UAA201908271 A UA A201908271A UA 124353 C2 UA124353 C2 UA 124353C2
Authority
UA
Ukraine
Prior art keywords
group
atom
pharmaceutically
acceptable salt
hydrogen atom
Prior art date
Application number
UAA201908271A
Other languages
English (en)
Inventor
Кейдзі Тамура
Кейдзи ТАМУРА
Такеру ЯМАКАВА
Сатосі Іссхікі
Сатоси Иссхики
Йосінарі Вакіяма
Йосинари Вакияма
Сохеі Оуті
Сохеи Оути
Такасі Мацухіра
Такаси Мацухира
Нацукі Ісіда
Нацуки Исида
Юдзі Табата
Юдзи ТАБАТА
Original Assignee
Мейдзі Сейка Фарма Ко., Лтд.
Мейдзи Сейка Фарма Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мейдзі Сейка Фарма Ко., Лтд., Мейдзи Сейка Фарма Ко., Лтд. filed Critical Мейдзі Сейка Фарма Ко., Лтд.
Publication of UA124353C2 publication Critical patent/UA124353C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Сполука, що описується загальною формулою (1), наведеною нижче, або її фармакологічно прийнятна сіль: , (1) у формулі (1): R1 і R2 можуть бути однаковими або різними і кожний означає атом водню, атом галогену, гідроксигрупу, карбоксигрупу, ціаногрупу, необов'язково заміщену C1-6-алкільну групу і ін.; R3 означає атом водню; R4 означає необов'язково заміщену 4-10-членну моноциклічну гетероциклічну групу, що містить від 1 до 4 гетероатомів, вибраних з атома кисню, атома азоту і атома сірки; X означає групу, що описується наступною формулою: -CH2-, -CH2-CH2-, -CH2-CH2-CH2- або -CH2-O-CH2-; і Z означає атом водню або гідроксигрупу.
UAA201908271A 2016-12-26 2017-12-26 Нова сполука і її фармакологічно прийнятна сіль UA124353C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016251577 2016-12-26
JP2017089251 2017-04-28
PCT/JP2017/046610 WO2018124060A1 (ja) 2016-12-26 2017-12-26 新規化合物及びその薬理的に許容される塩

Publications (1)

Publication Number Publication Date
UA124353C2 true UA124353C2 (uk) 2021-09-01

Family

ID=62709343

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201908271A UA124353C2 (uk) 2016-12-26 2017-12-26 Нова сполука і її фармакологічно прийнятна сіль

Country Status (22)

Country Link
US (1) US10669283B2 (uk)
EP (1) EP3560925B1 (uk)
JP (1) JP6815417B2 (uk)
KR (1) KR102414365B1 (uk)
CN (1) CN110114358B (uk)
AU (1) AU2017385199B2 (uk)
BR (1) BR112019010571A2 (uk)
CA (1) CA3048170A1 (uk)
CY (1) CY1124643T1 (uk)
DK (1) DK3560925T3 (uk)
ES (1) ES2875548T3 (uk)
HU (1) HUE055468T2 (uk)
IL (1) IL267594B (uk)
MX (1) MX2019007684A (uk)
PH (1) PH12019501391A1 (uk)
PL (1) PL3560925T3 (uk)
PT (1) PT3560925T (uk)
RU (1) RU2767878C2 (uk)
TW (1) TWI752141B (uk)
UA (1) UA124353C2 (uk)
WO (1) WO2018124060A1 (uk)
ZA (1) ZA201904241B (uk)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112312914A (zh) * 2018-06-27 2021-02-02 明治制果药业株式会社 炎症性疾病、自身免疫疾病、纤维化疾病、及癌症疾病的治疗剂
JP2021155336A (ja) * 2018-06-27 2021-10-07 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 新規ｐｄｅ４阻害剤
AR114977A1 (es) * 2018-06-27 2020-11-11 Meiji Seika Pharma Co Ltd Cristales de derivado de benzoxazol
WO2020221824A1 (en) 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv)
CN111057075B (zh) * 2019-12-24 2021-04-27 武汉九州钰民医药科技有限公司 Ret抑制剂及其制备方法
EP4365174A1 (en) 2021-06-30 2024-05-08 Meiji Seika Pharma Co., Ltd. Method for producing benzoxazole derivative having bicyclic piperazine ring or salt thereof, and method for producing material thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61166827A (ja) 1985-01-17 1986-07-28 Toray Ind Inc 変性エポキシ系微粒子
JP3193560B2 (ja) 1993-04-16 2001-07-30 明治製菓株式会社 新規ベンゾオキサゾール誘導体
JP3520177B2 (ja) 1996-05-09 2004-04-19 明治製菓株式会社 セロトニン５−ｈｔ３受容体部分活性薬
GB0003256D0 (en) 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
SK288115B6 (sk) * 2002-09-25 2013-09-03 Memory Pharmaceuticals Corporation Indazoles, pharmaceutical compositions comprising them and their use
MX2007010063A (es) * 2005-02-17 2008-01-16 Albany Molecular Res Inc Benzoxazol-carboxamidas para el tratamiento de la naucea y el vomito inducidos por quimioterapia y sindrome del intestino irritable con diarrea predominante.
CA2660349A1 (en) 2006-08-07 2008-02-14 Albany Molecular Research, Inc. 2-aminobenzoxazole carboxamides as 5ht3 modulators
EP2215093B1 (de) * 2007-10-19 2011-12-14 Boehringer Ingelheim International GmbH Neue piperazino-dihydrothienopyrimidin-derivate
ES2714705T3 (es) * 2013-07-10 2019-05-29 Meiji Seika Pharma Co Ltd Inhibidor de PDE4 novedoso

Also Published As

Publication number Publication date
PT3560925T (pt) 2021-07-28
RU2019122999A3 (uk) 2021-03-31
US20190322686A1 (en) 2019-10-24
WO2018124060A1 (ja) 2018-07-05
ZA201904241B (en) 2020-12-23
ES2875548T3 (es) 2021-11-10
CN110114358A (zh) 2019-08-09
KR20190097235A (ko) 2019-08-20
EP3560925A1 (en) 2019-10-30
DK3560925T3 (da) 2021-06-28
RU2767878C2 (ru) 2022-03-22
RU2019122999A (ru) 2021-01-26
KR102414365B1 (ko) 2022-07-01
IL267594B (en) 2022-04-01
EP3560925B1 (en) 2021-06-02
JP6815417B2 (ja) 2021-01-20
AU2017385199A1 (en) 2019-07-04
TWI752141B (zh) 2022-01-11
NZ754689A (en) 2024-04-26
US10669283B2 (en) 2020-06-02
CN110114358B (zh) 2021-12-03
PH12019501391A1 (en) 2020-02-10
HUE055468T2 (hu) 2021-11-29
JPWO2018124060A1 (ja) 2019-10-31
CY1124643T1 (el) 2022-11-25
MX2019007684A (es) 2019-09-09
PL3560925T3 (pl) 2021-12-20
CA3048170A1 (en) 2018-07-05
TW201835080A (zh) 2018-10-01
AU2017385199B2 (en) 2021-09-09
EP3560925A4 (en) 2020-06-10
BR112019010571A2 (pt) 2019-09-17

Similar Documents

Publication Publication Date Title
PH12019501391A1 (en) Novel compound and pharmacologically acceptable salt thereof
TN2018000262A1 (en) Substituted piperidine compound and use there of.
NZ629025A (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
MX2017005769A (es) Derivados policiclicos activos como plaguicidas con sustituyentes que contienen azufre.
MY192059A (en) Heterocyclic amides as kinase inhibitors
UA116794C2 (uk) Моноциклічна піридинова похідна
MX2018000394A (es) Eteres ariloxipirimidinilicos como herbicidas.
BR112015016580A2 (pt) composto heterocíclico contendo nitrogênio ou sal deste
MY182124A (en) Pesticidally active heterocyclic derivatives with sulphur containing substituents
PH12015500209A1 (en) Partially saturated nitrogen-containing heterocyclic compound
MX2018003554A (es) Benzamidas sustituidas con isoxazolina y analogos como insecticidas.
MX2016012448A (es) Derivados heterociclicos que contienen sustituyentes de tipo azufre activos como plaguicidas.
MX2010013939A (es) Derivados de n-oxido pirazina sustituidos.
MX2009011769A (es) Derivados de piridona como inhibidores de mapk p38a.
CY1121626T1 (el) Νεο παραγωγο υδροξαμικου οξεος ή αλας αυτου
MY178881A (en) Novel aqueous composition
PH12017500530B1 (en) Isoxazole derivative as mutant isocitrate dehydrogenase 1 inhibitor
MX2013007938A (es) Compuesto biciclico novedoso o sal del mismo.
MX2022003145A (es) Compuestos de amina ciclica activos como plaguicidas.
ZA201805790B (en) Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and &#34;azd9291 aniline&#34; or a salt thereof
MX2017001064A (es) Piridonas como herbicidas.
SG11201810725WA (en) Novel β-lactamase inhibitors
BR112013024957A2 (pt) derviado de furanona ou um sal farmaceuticamente aceitável do mesmo
MX2015007309A (es) Derivado de hidantoina.
MX2018000599A (es) Compuesto heterociclico que contiene nitrogeno.